阿斯利康 AZN 深 沪
等待开盘 01-10 09:30:00 美东时间
94.70
+0.690
+0.73%
华盛通- 最 高95.935
- 今 开95.22
- 成交量 469.98万股
- 最 低 94.535
- 昨 收 94.01
- 总市值 2936.65亿
- 52周最高 96.51
- 市盈率 静 42.06
- 换手率 0.15%
- 52周最低 60.735
- 委 比 78.26%
- 总股本 31.01亿
- 历史最高 96.51
- 量 比 1.15
- 振 幅 1.49%
- 历史最低 3.59
- 每 手 1
- 风险率 8.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AstraZeneca’s DAHLIA Lupus Study: Real‑World Data Could Strengthen Anifrolumab’s Long‑Term Investment Case
AstraZeneca ($AZN) announced an update on their ongoing clinical study. Study O...
今天 00:32
AstraZeneca Clears an Early Safety Hurdle With AZD0780–Metformin Interaction Study
AstraZeneca ($AZN) announced an update on their ongoing clinical study. AstraZe...
今天 00:30
汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作
汇宇制药(688553.SH)发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片(项目研发代号为“HY-0006”)是一种高选择性SOS1小...
01-09 16:27
强生(JNJ.US)加入降价药企阵营：与特朗普政府达成协议，以换取关税豁免
强生(JNJ.US)周四表示，已与美国总统特朗普政府达成协议，降低美国药品价格，以换取美国关税豁免。强生是继葛兰素史克(GSK.US)、默沙东(MRK.US)和...
01-09 10:51
Cellectis Announces 2026 Strategy and Catalysts
Cellectis outlines its 2026 strategic priorities, focusing on advancing allogeneic CAR-T therapies. Key catalysts include interim data for lasme-cel in r/r B-ALL from the pivotal Phase 2 BALLI-01 trial, Phase 1 data for eti-cel in r/r NHL, and leveraging partnerships with AstraZeneca, Servier/Allogene, and Iovance. Lasme-cel Phase 1 results show 68% ORR and favorable safety, while eti-cel demonstrates 88% ORR in Phase 1. The company expects to pr...
01-08 21:30
AstraZeneca shares are trading higher after the company announced results from the Phase III TULIP-SC trial.
AstraZeneca shares are trading higher after the company announced results from ...
01-06 23:21
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial
AstraZeneca reports positive results for subcutaneous administration of anifrolumab in Phase 3 TULIP-SC trial for lupus.
01-06 19:43
AMD and its Partners Share their Vision for “AI Everywhere, for Everyone” at CES 2026
AMD在CES 2026的主题演讲中展示了其在人工智能领域的最新进展。公司推出了“Helios” rack-scale平台，用于构建大规模的AI基础设施，展示了MI440X GPU，预告了MI500系列，并推出了消费者级AI处理器和开发者平台。此外，AMD承诺投入$1.5亿推动AI教育普及。
01-06 04:30
CVS, Astra, Cardinal to continue record setting rally into 2026: Barron’s
Barron’s issued positive views on CVS Health (CVS), AstraZeneca (AZN), and Cardinal Health (CAH) on Friday, arguing that the trio of healthcare stocks, which recorded their best performances in decade...
01-03 03:45
